[Yolk sac tumor of primary orbital localization].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to A Roth.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Morphine 0.3 mg kg-1 was i.m. given to 25 patients after upper abdominal operations, for analgesia purpose. One hour later, naloxone 0.01 mg was injected i.v. for every 1 mg morphine given. Ten minutes later, pentazocine 0.5 mg kg-1 was also injected i.v. in order to appreciate how it could counteract the reduction in analgesia level caused by naloxone. Complete analgesia could be found in all patients after the mentioned dose of morphine. The minute-ventilation and respiratory frequency were reduced from 7.74 +/- 0.66 to 6.88 +/- 0.77 l (decrease not significant J and from 22.76 +/- 0.98 to 17.44 +/- 0.88 (p less than 0.001). Naloxone partially restored their values, to 7.70 +/- 0.55 l and 18.96 +/- 0.88, but 17 patients out of 25 immediately complained of wound pain. Pentazocine improved analgesia again, in all patients, but also depressed the minute-ventilation to 6.43 +/- 0.48 l, without evident changes in respiratory frequency. If the respiratory changes after morphine and naloxone-pentazocine are compared, it is to emphasize that the distribution of the values was much less after the drug combination, 0.56 in comparison with 1.44, P (Fischer Snédécor test) less than 0.001, showing a more homogeneous improving of the minute-ventilation. In conclusion, if pentazocine is added to naloxone, while a respiratory depression caused by morphine has to be reversed, the analgesia level is maintained and the respiration is insignificantly reduced.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
We report a case of a newborn female which showed, at birth, a right cervical tumour of 12 cm of diameter. Macroscopically it was a cystic tumour with a 2 cm nodule. Microscopic examination showed different components such as nervous tissues. Striated and smooth muscle fibers were identified too. Latero cervical fistulas, branchial cysts, cystic hygroma, hemangiolymphangiomas and thyroid tumours must be considered as differential diagnosis.
Explore the source record for details and available documents.
Peripheral blood monocytes from 10 systemic lupus erythematosus (SLE) and 10 rheumatoid arthritis (RA) patients as well as from 24 controls were studied for such functions as phagocytosis, bactericidal capacity, iodination, and PGE2 production. Phagocytosis of opsonized erythrocytes, exploring only the Fc receptor, was increased in SLE and RA. Killing of Staphylococcus aureus was decreased in both SLE and RA in the presence of AB serum, but not in the presence of autologous serum. Iodination was, on the average, normal in SLE and elevated in RA. Prostaglandin E2 production was decreased in SLE (except with the highest concentration of Con A) and increased in RA. In SLE, functional alterations were more pronounced in clinically active than in inactive disease. These results show that in SLE and RA peripheral blood monocytes have alterations of their functions that are independent of serum factors. It is suggested that these abnormalities may be relevant to the pathogenetic mechanisms and evolution of these diseases.
In 32 cases of non-seminoma germinal tumours of the testis, correlations were established between the presence in situ of beta HCG and alpha foetoprotein, as demonstrated by the PAP immuno-peroxidase technique, the results of serum radioimmunological assays and the clinical course of the disease. It appeared that beta HCG-secreting mononucleate cells were present side by side with multinucleate syncytiotrophoblastic cells and that the immunohistological technique gave "earlier" results than the radioimmunological assays. The demonstration by this technique, in stage II dysgerminomas, of a cryptocellular trophoblastic carcinoma with beta HCG-secreting mononucleate cells indicates a highly malignant germinal tumour.
In 18 cases of seminoma of the testis correlations were established between beta HCG secretion, as demonstrated by the PAP immunoperoxidase technique, serum radioimmunological assays and clinical course of the disease. Mononucleate beta HCG-producing cells were found side by side with multinucleate syncytiotrophoblastic cells. This information was obtained earlier with the immunohistochemical technique than with radioimmunological assays. The immunoperoxidase technique makes it possible to detect mononucleate beta HCG-positive cell cryptocarcinomas which, when present in stage II seminomas, constitute a very dangerous dysgerminal tumour.
In cytostatic drug treatment, nausea and vomiting are very frequent, unpleasant and undesirable side effects that cause considerable discomfort to the patient. However, many established antiemetics (Torecan, haloperidol, Valium, Largactil etc.) have not shown significant antiemetic activity in the patients to whom cytostatics were applied. In our controlled randomized clinical trial, the antiemetic activity of methylprednisolone was investigated and compared with placebo (10 ml saline) and Torecan. All the compounds were injected before cis-platinum administration, knowing that this agent induces vomiting in almost 100% of patients. Ninety patients entered the study and have been evaluated. The results of the trial have shown that methylprednisolone in the single dose of 250 mg applied i.v. 2 h before injection of a cytostatic agent experienced pronounced antiemetic activity in 48% of the patients (15/31), as compared to Torecan 21% (6/29) and placebo 13% (4/30). This difference was statistically significant (P less than 0.01). No side effects were recorded after methylprednisolone application. The results of the study showed that methylprednisolone possesses a pronounced antiemetic activity in almost half of the patients treated with cis-platinum.
Explore the source record for details and available documents.
A phase II clinical trial was set up in metastatic breast cancer patients who had not received previous cytotoxic drug therapy, involving the administration of cis-dichlorodiammine platinum (cis-DDP). Patients aged up to 75 years and with pathohistologically confirmed disease were entered on the trial. All patients had measurable disease, a performance status (Karnofsky) of greater than 40, and an expected survival of greater than 6 weeks. In all 38 patients entered the trial, and 35 have been evaluated. The predominating metastatic sites included soft tissues (19), visceral organs (12), and bones (7 patients). cis-DDP was administered in a daily dose of 30 mg/m2 IV by a 4-h drip for 4 days, with customary hyperhydration. The results indicate a pronounced antitumorigenic effect of cis-DDP and a response rate of 54% (19/35), with 13 complete remissions (37%) and six partial remissions (17%). In terms of site the best response was obtained in soft-tissue processes (13/19; 68%), followed by visceral organs (4/10; 40%); the response rate was lowest in bones (2/6; 33%). The menopausal status and prior hormone therapy did not essentially influence the results of treatment, unlike previous irradiation. Patients with a lower performance status (40-70) had a significantly lower response rate (36% vs 63%; P less than 0.05). Toxic side-effects were moderate and did not substantially affect the general condition of the patients. A transient increase of serum creatinine was observed in 4 patients, and neurotoxicity in 2 patients. The results of the trial warrant the conclusion that cis-DDP has a pronounced antitumorigenic effect in untreated metastatic breast cancer, particularly in soft-tissue metastases. These results call for additional clinical study of the cytotoxic effect of cis-DDP in untreated metastatic breast cancer.
Explore the source record for details and available documents.
A 9-year-old boy with cyanotic congenital heart disease demonstrated congenital horizontal gaze paralysis and dysplasia of the left external and middle ear. Another patient associating congenital horizontal gaze paralysis and left hemifacial atrophy including ear dysplasia had previously been reported. The coincidence of such rare dysgenetic phenomena as congenital horizontal gaze paralysis and ear dysplasia in 2 patients seems to be significant. Since patients with congenital horizontal gaze paralysis often replace lateral gaze by convergence spasms, gaze paralysis sometimes remains undiagnosed. Therefore, when ocular motor disturbance is associated with ear dysplasia, the possibility of congenital horizontal gaze paralysis should be considered.
Serum somatomedin B levels were determined by radioimmunoassay in 209 healthy boys and girls from one month to 16 years of age. Low values were found up to the second year life. In the first year the mean level was 13.8 mg/l in girls and 11.5 mg/l in boys. In older children the values increased to levels between 13 and 22 mg/l in boys and between 13 and 18.5 mg/l in girls. They were independent of the stage of pubertal development. Somatomedin B levels were normal in 71 children with constitutional growth delay, primordial dwarfism, familial dwarfism and other forms of growth disturbance. The mean levels were between 12.1 and 14.4 mg/l. Values below 6 mg/l were present only in children with hGH deficiency. In these patients we could find an increase of the mean level from 4.3 mg/l without therapy to 9.4 mg/l under treatment. Thus the determination of somatomedin B seems to be useful for the diagnosis of hGH deficiency.